

### **REMARKS**

Reconsideration of this application is requested in view of the amendments to the claims and the remarks presented herein.

The claims in the application are claims 1 to 8 and 11, all other claims having been cancelled.


Claims 1 to 4, 7, 8 and 11 were rejected under 35 USC 112, second paragraph, as being indefinite. The Examiner objected to the expression "monounsaturated or polyunsaturated" and claim 2 was rejected as lacking antecedent basis for "prodrugs" and the Examiner noted that R<sub>5</sub> and R<sub>7</sub> were interchanged with R<sup>5</sup> and R<sup>7</sup>.

Applicants respectfully traverse these grounds of rejection since the amended claims are believed to comply with 35 USC 112. the definition of R<sup>3</sup> has removed the objected to language and has been replaced by alkenyl and alkynyl which is clearly supported by the application. Claim 11 has been amended to recite the treatment of osteoporosis which is set forth in the application as filed and R<sup>5</sup> and R<sup>7</sup> have been cancelled. The term "prodrugs" has been deleted from claim 2. Therefore, the amended claims are believed to properly define the invention and withdrawal of these grounds of rejection is requested.

With respect to the enablement rejection, the reference to 3-deazapurine, 7-deazapurine and 7-deaza-8-azapurine has been deleted from the claims although Applicants do not agree with the Examiner's enablement rejection.

Since the amended claims are believed to properly define the invention, Applicants request favorable reconsideration of the application.

Respectfully submitted,  
Muserlian, Lucas and Mercanti

  
Charles A. Muserlian, 19.683  
Attorney for Applicants  
Tel. # (212) 661-8000

CAM:ds  
Enclosure